Company Cytori Therapeutics Inc Nasdaq

Equities

US23283K1051

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Inactive Instrument

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Companyâs Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.

USD in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical 100.0 %	0	100.0 %	5	100.0 %	+2,093.30%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	0	100.0 %	5	100.0 %	+2,093.30%

Managers	Title	Age	Since
Marc Hedrick CEO	Chief Executive Officer	61	02-09-30
Andrew Sims DFI	Director of Finance/CFO	51	20-02-05
Pius Maliakal CTO	Chief Tech/Sci/R&D Officer	-	23-07-26
Norman LaFrance CTO	Chief Tech/Sci/R&D Officer	76	21-12-07
Russ Havranek PRN	Corporate Officer/Principal	-	13-12-31

Members of the board	Title	Age	Since
Marc Hedrick CEO	Chief Executive Officer	61	02-09-30
Richard Hawkins CHM	Chairman	75	07-11-30
Robert Lenk BRD	Director/Board Member	75	20-02-29
J. Clowes BRD	Director/Board Member	70	20-02-29
Greg Petersen BRD	Director/Board Member	61	20-02-13
An van Es-Johansson BRD	Director/Board Member	64	19-12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	4,354,641	4,214,074 ( 96.77 %)	78,559 ( 1.804 %)	96.77 %

Name	Equities	%	Valuation
Renaissance Technologies LLC 0.7717 %	33,000	0.7717 %	59 565 $
Vanguard Group, Inc. (Subfiler) 0.7610 %	32,541	0.7610 %	58 737 $
Geode Capital Management LLC 0.6207 %	26,543	0.6207 %	47 910 $
Robert Lenk 0.5884 %	25,160	0.5884 %	45 414 $
Greg Petersen 0.5652 %	24,167	0.5652 %	43 621 $
Citadel Securities GP LLC 0.3938 %	16,839	0.3938 %	30 394 $
Ground Swell Capital LLC 0.3345 %	14,303	0.3345 %	25 817 $
J. Clowes 0.2735 %	11,693	0.2735 %	21 106 $
UBS Securities LLC 0.2081 %	8,899	0.2081 %	16 063 $
BlackRock Institutional Trust Co. NA 0.1628 %	6,960	0.1628 %	12 563 $

Name	Equities	%	Valuation
Marc Hedrick 3.731 %	35	3.731 %	63 $
Richard Hawkins 1.066 %	10	1.066 %	18 $
Tiago Girão 0.1066 %	1	0.1066 %	2 $

Plus Therapeutics, Inc.

4200 Marathon Boulevard Suite 200

78756, Austin

+737 255 7194

http://www.plustherapeutics.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	-1.82%	41.35B
LONZA GROUP AG	+44.25%	40.38B
MODERNA, INC.	+2.56%	39.05B
CELLTRION, INC.	-12.11%	26.67B
ICON PUBLIC LIMITED COMPANY	+3.09%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.16%	18.36B
MEDPACE HOLDINGS, INC.	+22.12%	11.6B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.74%	11.68B
UNITED THERAPEUTICS CORPORATION	+7.75%	11.15B

Other Biotechnology & Medical Research